NewAmsterdam Pharma (NAMS) & Its Rivals Critical Survey

NewAmsterdam Pharma (NASDAQ:NAMS) is one of 1,075 public companies in the “Pharmaceutical preparations” industry, but how does it compare to its competitors? We will compare NewAmsterdam Pharma to related businesses based on the strength of its dividends, analyst recommendations, earnings, institutional ownership, profitability, risk and valuation.

Profitability

This table compares NewAmsterdam Pharma and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	N/A	N/A	N/A
NewAmsterdam Pharma Competitors	-3,399.87%	-235.11%	-32.77%

Analyst Recommendations

This is a summary of current ratings and target prices for NewAmsterdam Pharma and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	0	0	5	0	3.00
NewAmsterdam Pharma Competitors	8691	22727	51098	1415	2.54

NewAmsterdam Pharma currently has a consensus price target of $43.00, suggesting a potential upside of 125.96%. As a group, “Pharmaceutical preparations” companies have a potential upside of 223.53%. Given NewAmsterdam Pharma’s competitors higher probable upside, analysts clearly believe NewAmsterdam Pharma has less favorable growth aspects than its competitors.

Institutional and Insider Ownership

89.9% of NewAmsterdam Pharma shares are owned by institutional investors. Comparatively, 44.0% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 20.8% of NewAmsterdam Pharma shares are owned by company insiders. Comparatively, 13.5% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk & Volatility

NewAmsterdam Pharma has a beta of 0.01, indicating that its share price is 99% less volatile than the S&P 500. Comparatively, NewAmsterdam Pharma’s competitors have a beta of 4.28, indicating that their average share price is 328% more volatile than the S&P 500.

Valuation and Earnings

This table compares NewAmsterdam Pharma and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
NewAmsterdam Pharma	$47.14 million	-$176.94 million	-10.12
NewAmsterdam Pharma Competitors	$9.91 billion	$136.15 million	-4.87

NewAmsterdam Pharma’s competitors have higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

NewAmsterdam Pharma beats its competitors on 7 of the 13 factors compared.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.